A detailed history of Wealth Dimensions Group, Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Wealth Dimensions Group, Ltd. holds 4,525 shares of ABBV stock, worth $756,806. This represents 0.24% of its overall portfolio holdings.

Number of Shares
4,525
Previous 4,466 1.32%
Holding current value
$756,806
Previous $692,000 19.08%
% of portfolio
0.24%
Previous 0.22%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $9,429 - $10,743
59 Added 1.32%
4,525 $824,000
Q4 2023

Feb 09, 2024

BUY
$137.6 - $154.97 $19,814 - $22,315
144 Added 3.33%
4,466 $692,000
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $12,557 - $14,537
94 Added 2.22%
4,322 $644,000
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $15,768 - $19,623
119 Added 2.9%
4,228 $569,000
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $28,488 - $32,808
-197 Reduced 4.58%
4,109 $654,000
Q4 2022

Feb 10, 2023

BUY
$138.31 - $165.87 $13,831 - $16,587
100 Added 2.38%
4,306 $696,000
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $5,368 - $6,157
-40 Reduced 0.94%
4,206 $565,000
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $14,312 - $18,195
-104 Reduced 2.39%
4,246 $650,000
Q1 2022

May 04, 2022

SELL
$131.98 - $163.75 $14,253 - $17,685
-108 Reduced 2.42%
4,350 $705,000
Q4 2021

Feb 04, 2022

SELL
$107.43 - $135.93 $4,404 - $5,573
-41 Reduced 0.91%
4,458 $604,000
Q3 2021

Nov 03, 2021

BUY
$106.4 - $120.78 $10,533 - $11,957
99 Added 2.25%
4,499 $485,000
Q2 2021

Aug 12, 2021

SELL
$105.21 - $117.21 $29,669 - $33,053
-282 Reduced 6.02%
4,400 $496,000
Q1 2021

May 13, 2021

SELL
$102.3 - $112.62 $6,649 - $7,320
-65 Reduced 1.37%
4,682 $507,000
Q4 2020

Feb 17, 2021

BUY
$80.49 - $108.67 $382,086 - $515,856
4,747 New
4,747 $509,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Wealth Dimensions Group, Ltd. Portfolio

Follow Wealth Dimensions Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Dimensions Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Wealth Dimensions Group, Ltd. with notifications on news.